NEW YORK – NeoGenomics announced on Monday that it has entered a global strategic partnership agreement with Swiss proteomics firm Biognosys for biopharmaceutical research and development.
The agreement will encompass multiple strategic and commercial initiatives, including NeoGenomics' labs offering access to Biognosys proteomics platforms, medical and scientific affairs joint presentations and discussions, and global scientific and technical initiatives, NeoGenomics said in a statement.
Financial and other terms of the deal were not disclosed.
"Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics, and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care," Gina Wallar, NeoGenomics' president of pharma services, said in a statement.
The companies have designed a multi-modality approach for protein analysis of tumor samples from late-stage melanoma patients who have been treated with immune checkpoint inhibitors, NeoGenomics said. The collaboration combines Biognosys' TrueDiscovery proteomics platform, which is based on proprietary mass spectrometry technology, with NeoGenomics' proprietary MultiOmyx platform for multiplexed immunofluorescence spatial tissue analysis, the Fort Myers, Florida-based firm added.
Data from the collaboration will be presented at the American Association for Cancer Research this week.